Articles tagged with Drug Combinations
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
Researchers have found that combining DNMT and EZH2 inhibitors activates viral mimicry in cancer cells, making them more susceptible to attack by the immune system. The combination therapy has shown potential in treating colorectal cancers and other solid tumors, with an upcoming Phase I clinical trial planned.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
A new nanofluidic implant has been shown to deliver an HIV drug with increased potency compared to existing oral medications, providing a potential breakthrough in addressing treatment nonadherence. The device is intended for long-term controlled release and avoids repeated systemic treatment, which can lead to adverse side effects.
The University of Cincinnati Cancer Center team has opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, a deadly form of brain tumors. The treatment uses letrozole, a drug that targets an enzyme present in breast cancer cells, and temozolomide, a chemotherapy drug already approved as a GBM treatment.
A comparative study of four major type 2 diabetes medications reveals differences in medication acceptance, quality of life, insulin secretion, and mortality. The GRADE Study found that younger age and higher blood sugar levels at baseline were associated with poor blood sugar control over time.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
Research highlights treating anxiety and depression in people with heart disease can significantly reduce emergency room visits, hospitalizations, and even death. The study found that talk therapy and antidepressant medications improved heart outcomes among those with blocked arteries or heart failure.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
Recent medications for Type 2 diabetes and weight loss have positive effects on cardiovascular and kidney health but are not always prescribed or accessible to those who need them. The studies highlight the need to address barriers to access and equity, particularly among Black adults with severe obesity.
A new study found that peer-coaching is effective in controlling high blood pressure, particularly among younger Black patients. Participants under 60 who received peer coaching experienced a medically significant reduction in systolic blood pressure compared to those receiving enhanced usual care. The study also showed promise for pra...
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
Researchers investigated the impact of senolytic treatments on DNA methylation clocks and epigenetic age. Results showed significant increases in epigenetic age acceleration with Dasatinib and Quercetin treatment, but not with Fisetin addition.
The NCI-MATCH precision medicine trial discovered that trastuzumab-pertuzumab, approved for HER2-positive breast cancer, can shrink tumors in patients with other types of cancer and high levels of the HER2 gene. The study found a 12% confirmed overall response rate, with partial responses in various cancers.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
Researchers at Johns Hopkins Medicine have reported promising results from a clinical trial testing a novel immunotherapy combination to target advanced, potentially lethal skin cancers in kidney transplant patients. Two out of six patients experienced complete tumor regression after adding a second checkpoint inhibitor to the regimen.
A combination of CS1002 and CS1003 showed promising anti-tumor activity and a manageable safety profile across various dosing ranges in patients with advanced solid tumors. The treatment was found to be effective in certain types of cancers, including melanoma and skin cancer.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
Researchers identified a putative paclitaxel response predictive biomarker for glioblastoma and breast cancer using the whole genome CRISPR knockout screen. The biomarker candidate was validated in two independent breast cancer patient cohorts that received taxane treatment.
A new study aims to enhance and prolong vaccine effectiveness by delivering adjuvants to white blood cells using lipid nanoparticles. The research, led by WVU professor Sharan Bobbala, has the potential to provide broader protection against evolving viruses and multiple diseases.
Researchers at Baylor College of Medicine have developed a novel combination therapy that produced encouraging results in animal models. The therapy, which includes an inhibitor of the enzyme histone deacetylase (HDAC), showed significant tumor shrinkage and reduced alpha fetoprotein levels after just one week of treatment.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
A novel three-drug combination of an HDAC inhibitor with two types of immunotherapy achieved a 25% overall response rate and 50% progression-free survival in women with advanced HER2-negative breast cancer. Patients with triple-negative breast cancer had a higher response rate, highlighting the need for further clinical evaluation.
Researchers have developed a new approach to treating cutaneous neurofibromas, a common skin tumor associated with neurofibromatosis type 1. By targeting the cAMP and Ras/MAPK pathways, this combination therapy may provide an enduring halt in the expansion of these tumors.
A new clinical trial demonstrates a small reduction in the latent reservoir of HIV-infected cells using a combination of vorinostat and immunotherapy. While the results are promising, further research is needed to create more effective approaches to flush out the virus and attack it when it emerges from latency.
The study evaluated the effectiveness of ruxolitinib in treating relapsed/refractory multiple myeloma. Researchers found that ruxolitinib inhibited JAK signaling, leading to enhanced anti-tumor effects and improved patient outcomes.
Researchers have developed a new treatment combining immunotherapy with lab-cultivated T-cells from patients' blood, which significantly inhibits triple-negative breast cancer growth and metastasis. The treatment has shown promising outcomes in animal models, but further testing in humans is needed to confirm its effectiveness.
The University of Texas at Arlington is advancing its understanding of deadly disease tuberculosis (TB) with a new research project led by associate professor Kayunta Johnson-Winters. The project aims to understand why certain types of Mycobacterium tuberculosis bacteria do not respond to treatments.
A preliminary study found that most stroke survivors can safely take two common types of antidepressants without increasing the risk of hemorrhagic stroke. However, patients on dual anti-platelet therapy may be at increased risk of bleeding.
A combination of two cancer drugs has shown promise in treating malignant peripheral nerve sheath tumors (MPNSTs), a type of cancer that is notoriously hard to treat. The study found that the combination therapy of SHP2 inhibitors and CDK4/6 inhibitors suppressed tumor growth and triggered cell death in mouse models.
Researchers found that hepatitis E virus (HEV) mutations made treatment with individual drugs less effective, highlighting the need for combination therapies. The study's findings also provide insights into the evolutionary dynamics of HEV, paving the way for next-generation antiviral treatments.
Dr. Mikhail V. Blagosklonny, a renowned oncologist, shares his personal journey with metastatic brain cancer and challenges conventional treatment approaches. He argues that targeted drugs alone cannot cure lung cancer, but preemptive combinations may offer hope.
A new international trial investigated the safety and efficacy of sabatolimab combined with hypomethylating agents in patients with myelodysplastic neoplasms. The study found manageable side effects, but no significant improvement in response rates or progression-free survival.
A study led by Amsterdam UMC found that a tailored computerised decision support system reduced high-risk drug combinations and improved patient safety. The system only showed alerts for high-risk or needing extra monitoring, resulting in 12% fewer high-risk drug combinations and shorter ICU stays.
A recent trial assessed a novel combination of local vibration and extracorporeal shock wave therapy for the effective treatment of plantar fasciitis, with results showing significant reductions in plantar fascia thickness and heel pain. The study highlights a promising therapeutic intervention to treat this common musculoskeletal cond...
Researchers identified gartisertib as a potent ATR inhibitor that enhances cell death in patient-derived glioblastoma cell lines. The study also showed synergy between gartisertib and TMZ+RT treatment, with higher sensitivity to gartisertib observed in MGMT promoter unmethylated cells.
Researchers at Kennedy Krieger and Boston Children's Hospital have discovered a new way to decrease early seizure likelihood among infants with Sturge-Weber Syndrome. Presymptomatic treatment involving anti-seizure medication and low-dose aspirin improves neurologic outcomes.
Researchers found a combination treatment involving high doses of radiation and chemotherapy to be safe and effective in treating locally advanced non-small cell lung cancer. The treatment, which includes an adaptive boost plan, showed promising results in improving progression-free survival and reducing toxic side effects.
A study by Virginia Tech researchers found that medications used to treat Type 2 diabetes, such as Ozempic and Mounjaro, can decrease cravings for alcohol and lead to reduced consumption in individuals with obesity. The findings add to a growing literature on the potential of GLP-1 agonists to curb dangerous drinking habits.
Scientists have mapped neuroblastoma tumors at the cell level and discovered a brake on the immune system that can be blocked with existing immunotherapy. A new combination treatment targeting TIGIT and PD-L1 is being developed, showing promising results in lab experiments.
Researchers discovered new antibiotic molecules targeting Mycobacterium tuberculosis, reducing its pathogenicity. These substances also enhance the activity of conventional antibiotics like ethionamide, offering a renewed treatment approach.
A Phase IIa international study found that a combination of zanidatamab, palbociclib, and fulvestrant improved progression-free survival by 12 months with durable responses. The treatment regimen is being developed for heavily pretreated patients with HER2+/HR+ metastatic breast cancer.
A two-year study found that participants who received personalized coaching experienced a modest boost in cognitive testing, measuring a 74% improvement over the non-intervention group. Additionally, improvements were noted between the two groups in measurements of risk factors and quality of life.
Researchers at UCSF and Kaiser Permanente Washington found that participants who received personalized coaching experienced a 74% improvement in cognitive testing compared to non-intervention participants. The study also showed improvements in risk factors and quality of life, with modest but significant increases in cognitive function.
Researchers found that people with overweight or obesity who took semaglutide for over 3 years had a 20% lower risk of heart attack, stroke, or death from cardiovascular disease. The study showed significant weight loss and improved cardiovascular outcomes in adults without diabetes.
A population-based study found a significant increase in overdose-related OHCA from 2015 to 2021, with opioid-stimulant cases having lower survival rates. The combination of increasing incidence and lower survival rates supports prevention and treatment initiatives tailored to drug-specific profiles.
A study at ACR Convergence 2023 found that hydroxychloroquine lowers the risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients, particularly in women and men under 50. The medication may exert its effect through increased adiponectin levels, a hormone inversely linked to insulin resistance and inflammation.
Researchers will investigate the brain's signaling pathways when xylazine and fentanyl are used together, with the goal of identifying potential therapeutic targets. The study could lead to new strategies for treating individuals struggling with combined substance use.
Researchers found that FAAH inhibition reduced breast cancer growth in immunodeficient mice and induced apoptosis of breast cancer cells. The combination of FAAH inhibitors and endocannabinoids was the most effective treatment approach.
A new therapeutic option has been found for patients with a treatment-resistant tumor mutation called KRAS G12C. The sotorasib and panitumumab combination demonstrated superior progression-free survival rates compared to standard of care.
A new neighborhood-based care model has been shown to be effective in treating hepatitis C among injection drug users and those experiencing homelessness. The study found that 92% of participants had undetectable levels of the virus after treatment, with 84% achieving sustained virologic response.
A new trial combining an Alzheimer's medication with two other drugs may amplify its effects and arrest disease progression. The trial, funded by a $150M grant, will recruit 900 participants with early-onset Alzheimer's.
Researchers discovered that inhibiting the BRAF/EGFR/MEK pathway significantly reduced cancer stemness and drug resistance in primary colorectal cancer cells. The study also identified a triple combination treatment against BRAF, EGFR, and MEK as a promising approach to block these activities and develop effective treatments.
Researchers have discovered a new mechanism for starving pancreatic cancer cells, potentially leading to improved treatment outcomes. A combination of treatments involving the drug DRP-104, which blocks glutamine metabolism, and trametinib, an existing ERK signaling pathway blocker, showed promising results in mouse models.
A Phase IIIb study published in the New England Journal of Medicine found that esketamine nasal spray achieved higher remission rates (27.1%) compared to quetiapine extended-release (17.6%) in patients with treatment-resistant depression, indicating its potential as a targeted therapy for this population.
A study at Ohio State University found that a combination of ibogaine hydrochloride and 5-MeO-DMT significantly improved PTSD symptoms, depression, anxiety, and cognitive functioning in special operations forces veterans. The treatment also alleviated cognitive impairment linked to traumatic brain injury.
A new study reveals that esketamine nasal spray is effective in treating treatment-resistant depression, with 27.1% of patients achieving remission after 8 weeks compared to 17.6% on quetiapine XR. Long-term data shows sustained remission rates at 21.7% for esketamine NS and 14.1% for quetiapine XR.
Researchers have developed a new approach to treating invasive bladder cancer, combining chemotherapy and immunotherapy, which may preserve quality of life. In a phase 2 clinical trial, approximately 43% of patients achieved complete response without surgical removal of the bladder.
A study showed that yoga therapy can improve heart failure patients' endurance, strength, balance, symptom stability, and overall quality of life. Additionally, echocardiographic parameters revealed improved left ventricular systolic function in the yoga group compared to the non-interventional group.